DeepMed Research

Cefoxitin

Generic Name: Cefoxitin

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₇N_₃O_₇S_₂

CAS Number: 35607-66-0

Unique Ingredient Identifier: 6OEV9DX57Y

Background: Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.

Indication: For the treatment of serious infections caused by susceptible strains microorganisms.

Associated Conditions: Abscess, Intra-Abdominal, Animal bite, Bacterial Infections, Bacterial Urinary Tract Infections, Bone and Joint Infections, Endometritis, Flu caused by Influenza, Gynecological Infection, Intraabdominal Infections, Lower respiratory tract infection bacterial, Lung Abscess, Pelvic Inflammatory Disease (PID), Pelvic cellulitis, Peritonitis, Pneumonia, Septicemia, Skin and Subcutaneous Tissue Bacterial Infections

Associated Therapies: Antibiotic pre-surgical prophylaxis

Clinical Trials

Precision Antibiotic Dosing for Appendectomy

Phase 1

Active, not recruiting

Conditions: Appendicitis (Diagnosis)

Interventions: Drug: Cefoxitin

First Posted Date: 2025-03-06

Last Posted Date: 2025-03-06

Lead Sponsor: University of Michigan

Target Recruit Count: 46

Registration Number: NCT06860802

Locations: 🇺🇸
Michigan Medicine, Ann Arbor, Michigan, United States

Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery

Phase 3

Recruiting

Conditions: Colorectal Surgery
Antibiotic Prophylaxis

Interventions: Drug: Loading bolus of cefoxitin
Drug: Intermittent cefoxitin
Drug: Continuous infusion of cefoxitin
Drug: Intermittent placebo
Drug: Continuous infusion of placebo

First Posted Date: 2023-03-06

Last Posted Date: 2024-04-23

Lead Sponsor: Poitiers University Hospital

Target Recruit Count: 2000

Registration Number: NCT05755789

Locations: 🇫🇷
CHU Angers, Angers, France
🇫🇷
CHU Clermont Ferrand, Clermont-Ferrand, France
🇫🇷
Hopital privé Arras les Bonnettes, Arras, France

and more 16 locations

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Phase 2

Recruiting

Conditions: Pulmonary Disease Due to Mycobacteria (Diagnosis)

Interventions: Drug: Amikacin
Drug: Tigecycline
Drug: Imipenem
Drug: Cefoxitin
Drug: Linezolid
Drug: Azithromycin
Drug: co-trimoxazole
Drug: Clarithromycin
Drug: Clofazimine
Drug: Doxycycline
Drug: Moxifloxacin
Drug: Ethambutol
Drug: Bedaquiline
Drug: Rifabutin

First Posted Date: 2020-03-17

Last Posted Date: 2024-12-11

Lead Sponsor: The University of Queensland

Target Recruit Count: 300

Registration Number: NCT04310930

Locations: 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺
Royal Melbourne Hospital, Parkville, Victoria, Australia

and more 47 locations

Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

Phase 3

Completed

Conditions: Pancreas Cancer
Pancreatic Diseases
Pancreatic Cancer

Interventions: Drug: Cefoxitin
Drug: Piperacillin-tazobactam

First Posted Date: 2017-09-01

Last Posted Date: 2025-05-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 958

Registration Number: NCT03269994

Locations: 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Hackensack Meridian Health / Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States

and more 29 locations

Immediate Versus Delayed Induction in Term-PROM Using or Not Antibiotic Prophylaxis

Not Applicable

Conditions: Maternal Infection During Pregnancy (Diagnosis)
Neonatal Infection

Interventions: Drug: Cefoxitin
Drug: oxytocin/misoprostol

First Posted Date: 2016-12-07

Last Posted Date: 2016-12-13

Lead Sponsor: Hospital de Santa Maria, Portugal

Target Recruit Count: 568

Registration Number: NCT02985086

Locations: 🇵🇹
Hospital de Santa Maria, CHLN, EPE, Lisbon, Portugal
🇵🇹
Hospital Garcia de Orta, EPE, Almada, Portugal

Study of Repeated Cefoxitin Administration in Major Abdominal Surgery Using a Microdialysis Technique

Phase 4

Completed

Conditions: Antibiotic Prophylaxis Surgery

First Posted Date: 2016-03-09

Last Posted Date: 2017-06-12

Lead Sponsor: Poitiers University Hospital

Target Recruit Count: 12

Registration Number: NCT02703857

Locations: 🇫🇷
Centre Hospitalier de Poitiers, Poitiers, France

Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli

Phase 4

Terminated

Conditions: Urinary Tract Infections

Interventions: Drug: Cefoxitin
Drug: imipenem

First Posted Date: 2015-06-18

Last Posted Date: 2017-08-11

Lead Sponsor: Central Hospital, Nancy, France

Target Recruit Count: 6

Registration Number: NCT02474706

Locations: 🇫🇷
CHRU Nancy, Nancy, France

Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli

Not Applicable

Terminated

Conditions: Acute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.Coli

Interventions: Drug: Cefoxitin

First Posted Date: 2013-03-29

Last Posted Date: 2018-01-12

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 9

Registration Number: NCT01820793

Locations: 🇫🇷
Agnès LEFORT, Clichy, France

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy